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Background: The activation of immune cells in the brain is believed to be one of the earliest events in prion
disease development, where misfolded PrionSc protein deposits are thought to act as irritants leading to a series of
events that culminate in neuronal cell dysfunction and death. The role of these events in prion disease though is
still a matter of debate. To elucidate the mechanisms leading from abnormal protein deposition to neuronal injury,
we have performed a detailed network analysis of genes differentially expressed in several mouse prion models.
Results: We found a master regulatory core of genes related to immune response controlling other genes involved
in prion protein replication and accumulation, and neuronal cell death. This regulatory core determines the
existence of two stable states that are consistent with the transcriptome analysis comparing prion infected versus
uninfected mouse brain. An in silico perturbation analysis demonstrates that core genes are individually capable of
triggering the transition and that the network remains locked once the diseased state is reached.
Conclusions: We hypothesize that this locking may be the cause of the sustained immune response observed in
prion disease. Our analysis supports the hypothesis that sustained brain inflammation is the main pathogenic
process leading to neuronal dysfunction and loss, which, in turn, leads to clinical symptoms in prion disease.
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Prion proteins are responsible for a class of fatal neuro-
degenerative diseases, which affect both humans and
animals. Prion disease, like other chronic neurodegen-
erative disease such as Alzheimer’s or Parkinson’s dis-
eases, belongs to the class of protein misfolding disease
that are characterized, pathologically, by abnormal pro-
tein deposition and the formation of amyloid plaques
[1]. Prion protein exists in major two isoforms: normal,
cellular prion protein (PrionC) and abnormal, misfolded
prion protein (PrionSc). In most forms of prion disease,
the misfolded isoform accumulates in extracellular
aggregates. Prion disease is transmissible, the primary* Correspondence: antonio.delsol@uni.lu
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reproduction in any medium, provided the orroute of infection being through the ingestion of abnor-
mal prions.
Several hypotheses have been put forward to explain
prion disease pathogenesis, such as PrionC loss-of-function,
PrionSc gain-of-toxic function, endoplasmatic reticulum
stress, activation of autophagy and/or apoptotic death
pathways, and chronic brain inflammation induced by
misfolded protein and neuronal injury [2], but none has
emerged so far as the main initiator and/or propagator of
the disease [3]. We have used a computational network
analysis based on known gene expression data to address
this complex question. Our analysis shows that it is brain
inflammation that plays a key role in prion disease. The
main cellular mediators of brain inflammation are micro-
glia, which are responsible for the first active immune re-
sponse in the brain. These cells are among the earliest
responders but their role in prion disease initiation and
progression is still debated. We have examined gene ex-
pression data from a recent comprehensive transcriptome
study on the initiation and progression of prion disease inLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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identified a limited number of immune response- related
genes as crucial factors in the disease process. These
genes appear to be capable of irreversibly locking a large
network of differentially expressed genes (DEG) into a
disease state, thus uncovering an essential process of the
early steps in disease progression.
There is increasing evidence that the brain and immune
system are connected: in both normal and pathological
conditions neurons are interacting with immune cells and
regulating their activity [5]. Chronic immune activation,
especially of microglia, is a common feature of chronic
neurodegenerative conditions such as Alzheimer’s and
Parkinson’s [6]. For example, there are many similarities
between Alzheimer’s disease and prion disease: both
diseases are characterized by the protein deposition, sig-
nificant neuronal degeneration and the morphological ac-
tivation of microglia and astrocytes [7]. In prion disease,
neuropathological data shows that microglia are among
the earliest responders to neurodegeneration [8,9] and
that microglia proliferate in response to disease-causing
prion protein deposition [10].
It has been proposed that diseased states correspond
to abnormal stable states in the gene expression land-
scape, or in other words, disease is reflected by long
term differential expression patterns [10][11]. The nat-
ural robustness of biological networks allows them to
maintain the organism in a healthy state despite the in-
fluence of a range of external and internal perturbations.
The network robustness is a topological property i.e. is a
result of specific connectivity between genes in question.
However, abnormal network states occasionally occur
under the influence of strong internal or external pertur-
bations (i.e. disease initiators or irritants), and these may
play an important role in disease initiation and progres-
sion. Thus a particular connectivity pattern that is re-
sponsible for the robustness of the healthy state can also
produce a robust diseased state.
Here we address the question of how a subset of genes
forming a master regulatory core in a gene regulatory
network is able to determine the stability of this network
in a prion disease context. A previous study has shown
that gene interactions forming small bi-stable circuits
are implicated in the resilience and progression of
human cancers, where the healthy and cancer states
were considered to be the two stable states [12]. How-
ever, how these isolated small bi-stable circuits contrib-
ute to the general mechanism of the network stability
(and hence cancer development) is still open. We ad-
dress this issue by significantly extending the idea of bi-
stable circuits to a more comprehensive mechanism, the
so called master regulatory core, which could explain
how the network shifts from the healthy to the diseased
stable state. During our analysis we realized that genesbelonging to the master regulatory core are highly con-
nected in the network and largely related to immune re-
sponse, supporting the idea of the central role of a
sustained inflammatory process leading to neuronal dys-
function and death in the prion disease progression.
Results
The global and core regulatory networks
Our initial goal was to build a gene regulatory network
based on the differentially expressed genes reported by
Hwang et al. [4]. The functional relationships, based on
gene expression, found in the literature resulted in a glo-
bal network consisting of 106 genes that are differen-
tially expressed during prion infection (all upregulated),
connected with 169 functional relations (all activations).
(Figure 1A and Additional file 1).
We then carried out stability analysis performed using
a boolean dynamical model to compute network stable
states. Afterwards, we identified a set of genes able to
trigger the transition between attractors and at the same
time lead to the network’s persistence in the diseased
state. Due to the possibility of there being incomplete in-
formation about gene-gene interactions even in the parts
of the network which are well known, we based our ana-
lysis and conclusions on the network stability and the
transition between stable states, avoiding a detailed de-
scription of transient states (potentially feasible given
that experimental data has several time points) that are
more sensitive to the lack of information.
Network dynamics are regulated by the structure of
the network through the flow of information through
feed-forward and feed-back loops. When we looked for
network structures with a exchange of information, we
found a unique strongly connected component (SCC)
consisting of 16 genes. The hallmark of such a structure
is that thanks to specific connectivity the information
can flow from one gene to any other in the structure fol-
lowing at least one path (see Methods for detailed expla-
nations). This mutual influence between any pair of
genes belonging to the SCC makes this structure rele-
vant in terms of information exchange, and therefore po-
tentially determinant for the network’s stability. The
SCC is mainly regulatory in nature with only 6 incoming
functional relations. This SCC constitutes the regulatory
core, and its regulatory impact extends up to 74 genes,
so the states of these 74 genes depend on the state of
the master regulatory core.
In order to analyze the stability of regulatory core
genes alone, we carried out a simulation of network dy-
namics to determine the stable states of this sub-
network in isolation using a Boolean dynamical model.
Two stable states were found for the regulatory core,
one with all nodes “off” and one with all nodes “on”.
Extending the simulation to cover genes regulated by
Figure 1 Fragmentation analysis of the global network. The
original global unfragmented network (a), the impact on the
network connectivity due to the removal of the sixteen genes
belonging to the SCC (b), and an example of the removal of sixteen
genes randomly selected (c). In (b) most of the genes become
disconnected and the size of the giant component or the biggest
connected graph is only 38 genes. In (c) when removing 16
randomly selected genes, the mean of the giant component was
81.02 nodes (standard deviation of 8.29) for 1000 removals . This
figure illustrates the relevant role of the SCC as a connectivity
element of the network.
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sistent results: again, we found two stable states, one
with all nodes “off” and one with all nodes “on”.
The perturbation analysis carried out using a con-
tinuous dynamical model showed that all regulatory
core genes were capable of triggering the transition
from the “off” to the “on” stable states in the core net-
work (Figure 2). But no gene was individually capable
of inducing the opposite transition, from the “off” to
the “on” state. Therefore, when the “on” state was
reached, the system staid locked despite external influ-
ences. Only simultaneous down regulation of a set of
nodes (theoretically possible but unlikely to occur in
practice) affecting several circuits in the regulatory
core would be able to reverse the “on” state; otherwise,
the system is irreversibly activated supporting the idea
that the regulatory core constitutes a master regulatory
switch that can be activated by external inputs and is
able to maintain the activation of a set of nodes that
may be relevant for the progression of prion disease.
Network properties
A network is constituted by nodes (i.e. genes) that are
inter-connected by edges (i.e. directed functional rela-
tions); expression of some genes can either activate or
inhibit expression of other genes in the network. There-
fore it is important to recognize genes that have more
control over the network. We applied two measures:
network fragmentation and betweenness centrality to
identify genes that play the role of so called communica-
tion hubs (mediators of interactions between other, more
peripheral genes). Fragmentation is a measure to assess
overall network connectivity and may be helpful to de-
termine the impact of a sub-network on global topology.
The fragmentation analysis of the global network pro-
duced the following results. The mean of the giant com-
ponent size for 1000 randomized removals of 16 nodes
was 81.02 nodes (standard deviation 8.29), while it was
only 38.00 nodes in the case of SCC node removal. The
difference between these values is 5.18 times the stand-
ard deviation of the random removal values. This indi-
cates that the size of the biggest set of connected nodes
Figure 2 Perturbation analysis of a gene in the SCC Perturbation of the TLR2 gene (black diamond), and its effect on the other genes
of the SCC. Y-axis: 0 indicates the “off” state, 1 indicates the “on” state. TLR2 is capable of triggering the transition from the “off” (healthy) to the
“on” (disease) stable state for all genes in the SCC. The simulations were performed assuming a continuous dynamical system where the initial
states are the attractors previously computed in a discrete model (Boolean). The Y-axis represents the “level of activity” in a range between 0 and
1, and X-axis represents “time” in arbitrary units.
Crespo et al. BMC Systems Biology 2012, 6:132 Page 4 of 12
http://www.biomedcentral.com/1752-0509/6/132was reduced dramatically when we removed the nodes
of the SCC instead of a random selection of 16 nodes
(Figure 1B and C). These results underlined the relevant
role of the SCC as a connectivity element of the global
network.The network presented here was scarcely intercon-
nected, which was also reflected in the betweenness
centrality analysis. There was a small group of central
genes (mostly belonging to SCC) that has a much lar-
ger number of peripheral genes in the network
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highly central (normalized betweenness > 1): TGFB1,
CSF1, TLR2, CEBPA, LGALS3 and STAT3. In total, 25
genes were not peripheral (i.e. they mediated at least
one gene connection). There was a significant differ-
ence when the betweenness centrality of genes partici-
pating in the SCC and the genes in the rest of the
network were compared. Median betweenness central-
ity in the SCC and global networks were 123 and 0,
respectively; the distributions in the two groups dif-
fered significantly (Mann–Whitney Wilcoxon W = 163,
n1 = 16, n2 = 90, p-value = 1.406e-10) supporting the
central role of the regulatory core in the global net-
work. It should be noted that the betweenness cen-
trality is more sensitive than other topological
features such as degree or clustering coefficient to
data incompleteness (missing genes or interactions)
because it depends on the global network structure
[13,14].
Having the hubs identified, we asked the question
whether the strong connectivity occurs between genes
involved in common or distinct biological processes.
Modules (clusters of genes sharing functional or topo-
logical properties) in the network were distinguished by
assigning the pathological prion disease processes
(derived from gene ontology annotations, described by
Hwang et al.) to genes constituting the network core.
Four modules were considered: disease-causing prion
protein (PrPSc) replication and accumulation, immune
response, neuronal cell death and other functions
(genes which could not be assigned to any of the previ-
ous groups). Inter-modular participation is a measure
for identifying genes which link different biological pro-
cesses and this measure was calculated for all module
members. Three groups can be distinguished according
to node role (see materials and methods): (1) one
connector hub with high inter-modular participation
(P > 0.60) and significant within-module connectivity
(z >2.5) at the same time highly central (normalized
centrality >1): TGFB1; (2) satellite connectors, (genes
with weak connectivity to other nodes of same function
but with high ratio of connections to other modules)
that share high centrality (normalized centrality >1):
CSF1, TLR2, LGALS3 and STAT3; (3) less high central
satellite connectors (positive normalized centrality):
CEBPD, STAT1 and B2M; (4) other non-central but
inter-module participative genes that are regulated by
the SCC and are associated with a different functional
category than the regulated gene or are regulating genes
of other functions: CASP1, CLU, TGFBR2, P2RX7,
NFATC1, CXCL10, CCND1, CYBB, AIF1 and GFAP. As
expected most of the selected hubs and connectors are
parts of SCC supporting its assumed role as a transition
driver.Functional analysis
We have categorized the genes of the core network with
regard to the four pathological features described by
Hwang et al. (Figure 3, Table 1). No genes from the
pathological feature category synaptic degeneration were
found in the core network, but it should be noted that
only one of the 333 DEGs in the original mouse study
was a member of this category.
A potential sequence of reactive changes has been pro-
posed by Hwang et al. and we have been able to identify
genes in our SCC and core network at each stage in this
proposed sequence. Transcriptome analysis suggested
that one of the first changes was the activation of the
complement pathways: the complement factor C3 is
located in the core network. Also, pattern recognition
receptors (PRRs) and other receptors may potentially
recognize PrPSc: ITGB2 and TLR2 in the SCC; CD14,
CD68, FCGR2B, TREM2 in the core network. Subse-
quently, the complement complexes and PRRs may be
responsible for stimulating the production of cytokines
(CSF1 in the SCC and CXCL10 in the core network) and
growth factors (TGFB1 in the SCC). They may also acti-
vate astrocytes, indicated by the increased expression of
the glial marker GFAP in the core network. Cytokines
released by microglia and astrocytes then lead to the ac-
tivation of endothelial cells, which would stimulate the
migration of leukocytes from the blood, followed by
their differentiation into microglia (leukocyte extravasa-
tion), involving ITGB2, NCF1, TGFBR1, TGFB1 in the
SCC and TGFBR2, ITGAX, CYBB in the core. The upre-
gulation of CSF1 (in the SCC) suggests that mono-
nuclear leukocytes (blood monocytes) may be converted
into microglia upon entering the brain.
Robustness of the results
In order to assess the effect the stringency in gene selec-
tion criteria could have on the network topology and dy-
namics, we reconstructed two additional networks based
on either more relaxed or constraint criteria for the gene
selection. This resulted, as expected, in a bigger and
smaller network respectively (see Additional file 1).
From the original list of 333 DEGs we selected genes
with p-value smaller than 0.01 on at least one time point
among three last time points and obtained a list of 226
differentially expressed genes resulting in a network of
27 nodes and 39 edges. Within this network we identi-
fied a SCC of 8 nodes and 13 edges (a subset of the ori-
ginal SCC with 16 nodes and 28 edges). This network
again showed a key role of genes involved in the inflam-
matory response and identical dynamical behavior with
two stable states matching experimental expression
values in healthy and diseased states. The betweenness
centrality of this network is significantly different be-
tween genes participating in the SCC and genes in the
Figure 3 Functional analysis of core network with pathological features Genes associated with PrPSc replication and accumulation are
in green, with nerve cell death in blue, with immune response (including, microglia/astrocyte activation, leukocyte extravasation,
general immune response) in pink. Other genes are indicated in grey. SCC genes are indicated as octagons.
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the SCC and the reduced version of the global networks
were 52.8 and 0, respectively; the distributions in the
two groups differed significantly (Mann–Whitney
Wilcoxon W = 3, n1 = 8, n2 = 19, p-value = 2.358e-5)
supporting the central role of the new regulatory core in
the reduced version of the global network.
The fragmentation analysis of this reduced version of
the global network produced the following results. The
mean of the giant component size for 1000 randomized
removals of 16 nodes was 13.88 nodes (standard devi-
ation 3.41), while it was only 5.00 nodes in the case of
the removal of the 9 remaining nodes from the original
16 (seven genes from the original 16 belonging to the
SCC are not included in this smaller network). Thedifference between these values is 2.59 times the stand-
ard deviation of the random removal values. This indi-
cates that despite the missing information it is still
possible to detect the importance in terms of connectiv-
ity of the 9 remaining key genes belonging to the SCC.
Next, we selected additional genes to expand the ori-
ginal network. This time we queried Prion Protein Data
Base (www.prion.systemsbiology.net) to include genes
previously not regarded as differentially expressed. To
limit the size of this extension we applied three step fil-
tering: 1) we looked for genes that could be upstream
and downstream of the original network (the same Path-
way Studio settings as in constructing original network);
2) p-value less than 0.01 among three last time points of
at least one prion-mouse strain combination; 3) sum of
Table 1 Summary of the genes and their functional categories
Biological function Genesa
Prp(Sc replication and accumulation A2M, ABCA1, ADAMTS1, APOD, PTGS1, SERPING1
Immune response
Complement activation: complement system C3
Complement activation: coagulation &
kallikrein system
PDPN, PROS1
Pattern recognition and other receptor CD14, CD68, ITGB2, FCGR2B, TREM2, TLR2
Microglia/astrocyte activation related GFAP, PTPN6, STAT1, STAT3, THBS2, TNFRSF1A, VIM
Cytokine, chemokine and growth factor related CSF1, CSF1R, CXCL10, CX3CR1
Leukocyte extravasation CYBB, ITGAX, NCF1, TGFB1, TGFBR1, TGFBR2
Other immune response AIF1, B2M, CD83, CD86, CEBPA, CEBPD,
Ctla2a, HLA-E, IFI27, IFIT3, NFATC1, SBNO2
Cell death CASP1, CCN D1, CLU, HSPB1, HSPB8, ID3, MCL1,
RBP1, SOCS3, TGM2
Other ALOX5AP, CD9, FLI1, GUSB, HPGD, IL13RA1,
INPP5D, ISG15, LCN2, LGAL53, LXN, MET, OSMR,
P2RX7, S100A4, SOX9, SRGN, SYNPO, TF
aGenes in the SCC are indicated in bold.
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tions less than mean. Applying this criteria we obtained
a list of 62 additional genes resulting in a network of
119 nodes and 389 edges. Within this network we
obtained one SCC of 82 nodes and 320 edges in which
the original SCC of 16 genes were embedded. This net-
work showed again a key role of genes involved in the
inflammatory response and identical dynamical behavior
with two stable states matching experimental expression
values in healthy and diseased states. The betweenness
centrality is again significantly different between genes
participating in the SCC and genes in the rest of the net-
work. Median betweenness centrality in the SCC and the
extended version of the global networks were 92.4 and
0, respectively; the distributions in the two groups dif-
fered significantly (Mann–Whitney Wilcoxon W = 326,
n1 = 83, n2 = 35, p-value = 1.02e-11). However, no sig-
nificant differences could be found between the
betweenness centrality of genes related with immune re-
sponse and the rest of the genes within the SCC in the
expanded network proving lack of topological bias of
this group of genes.
The fragmentation analysis of this expanded version of
the global network produced the following results. The
mean of the giant component size for 1000 randomized
removals of 16 nodes was 99.58 nodes (standard devi-
ation 2.76), while it was only 87 nodes in the case of the
removal of the 16 genes belonging to the original SCC.
The difference between these values is 4.54 times the
standard deviation of the random removal values. This
indicates that despite the noisy information the 16 nodes
belonging to the original SCC still show a remarkable
connectivity importance.In summary, the analysis of these reduced and
expanded networks supports the robustness of our find-
ings against both noisy and incomplete information.
Despite the lack of detailed mechanistic information
about specific pathways we still can gain insights into
the importance of neuroinflammation and immune re-
sponse in prion disease and their impact in the network
dynamics and disease progression.
Discussion
Prion diseases are a protein-based infectious diseases of
the nervous system that result in progressive and extensive
neurodegeneration throughout the brain. The mechanisms
leading to neurodegeneration are incompletely under-
stood, but loss of function of PrionC, gain-of-toxic func-
tion of PrionSc, activation of cellular and in particular ER
stress, neuronal death pathways such as autophagy and
apoptosis, and chronic brain inflammation all appear to
play a role. Experimental in vitro or in vivo approaches
typically investigate one of the potential pathogenic pro-
cesses at a time, and often quite elegantly demonstrate
their relevance in the disease process. However, to investi-
gate which of these processes is the most pathogenic and
contributes the most to the disease process, conventional
experimental approaches are more limited. To address this
issue, we therefore used a network analysis approach and
looked for a set of genes determining the stability of the
network using a Boolean dynamical system. By identifying
a set of core regulatory genes, most of which are part of
the immune response, that can lock a larger gene network
into a stable diseased state, we found that it is the process
of brain inflammation that is the most likely to play the
major pathogenic role in prion disease.
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Hwang et al. are related to the oxidative stress response,
only one of them is included in our global network
(PRDX6) and none in the core regulatory network. In
neurons, the accumulation of misfolded proteins also
leads to endoplasmic reticulum (ER) stress. The normal
unfolded protein response (UPR), which is a conse-
quence of the ER stress, should function to clear the
misfolded proteins. But it is thought that pro-
inflammatory cytokines released by microglia lead to an
upregulation of ER stress and an atypical form of UPR
in neurons [15-17]. Furthermore, it has been hypothe-
sized that prolonged ER stress activates cell death path-
ways [17,18]. Cellular stress is one of the possible
mechanisms triggering neurodegeneration. Necrosis in
acute brain injury is a result of the release of nitric
oxide, reactive oxygen species, calcium and glutamate
[6]. The role of prion in triggering the stress response is
still not understood, but a toxic effect caused by free
radicals produced due to an imbalance in the intracellu-
lar cupper levels has been previously associated with
prion disease and other neurodegenerative diseases
[19,20]. Whether this imbalance is due to the loss of
function (lack of prion directly or indirectly involved in
dismutase activity) or the gain of new functions (aggre-
gation of PrPSc) is still unclear, but there is evidence that
the toxicity results from prion dependent processes (al-
teration of PrP-mediated signaling, PrP mislocalization
and oligomerization) in murine models of scrapie [21].
The Ccaat-enhance binding protein (CEBP) transcrip-
tion factor family has been implicated in the differenti-
ation of myelomonocytic cells and the regulation of gene
expression during the activation of macrophages [22].
The isoform CEBPA regulates the expression of antioxi-
dant proteins. CEBPA-deficient mice were found to be
susceptible to hyperoxic conditions and prion was one
of the DEGs identified, thus suggesting a role of wild
type prion in lung injury [23]. Overexpression of the
CEBPD isoform is observed in Alzheimer’s [24] and in
prion disease [25]. Colony-stimulating factor 1 (CSF1)
and its receptor CSF1R are involved in the process of
macrophage DNA synthesis, which is induced by the
presence of amyloid beta and prion protein. The pres-
ence of misfolded amyloid beta precursor and prion pro-
tein promotes macrophage survival in bone marrow cells
[26]. Integrin beta 2 is encoded by ITGB2 and is known
to selectively bind to neuronal cells damaged by cleaved
prion. It is also involved in neuronal cell killing by acti-
vated microglial cells [27]. Transglutaminase 2 is
encoded by the TGM2 gene and may contribute to the
cross-linking of soluble peptides preventing amyloid for-
mation of alpha-synuclein or prion protein, thus increas-
ing concentrations of soluble toxic oligomers [28].
Overexpression of TGM2 is also observed in Huntingtonand Alzheimer’s diseases [29]. CX3CR1 is part of the
complement system and encodes the receptor for the
chemokine fractalkine. Antagonists of chemokine recep-
tors have been shown to play a neuroprotective role [30]
in several neurodegenerative diseases including prion
disease. Also, thiazolopyrimidine derivatives are antago-
nists of CX3CR1 and have been developed as drugs for
prion disease therapy [31]. TGFB1 is a cytokine which is
overexpressed in prion disease. Signaling through the
TGFB1 receptor is potentially responsible for the
chronic inflammatory processes by regulating an atypical
microglia phenotype [32]. LGALS3 encodes galectin-3, a
beta-galactoside binding lectin. It has been shown that
lectin binding and normal prion (PrPC) glycosylation are
altered during aging [33]. STAT1 transcription factor
signaling is increased in mouse models lacking PrPC,
indicating a neuroprotective role of PrPC [34,35]. The
STAT3 transcription factor is important for the
anti-apoptotic activity of humanin and therefore for
humanin-mediated neuroprotection after Alzheimer
disease-related insult [36]. The protective role of huma-
nin was also observed in prion disease [37].
The possible mechanistic links of the remaining genes
in the SCC (TLR2, NCF1, PTPN6 and B2M) to prion
disease are still open. Thus, these genes represent a new
set with a potential crucial function in prion disease
pathogenesis.
The gene product of TLR2, or Toll-like-receptor 2,
is a pattern recognition receptor found primarily on
innate immunity cells including microglia/macrophages
[38,39]). Although toll-like receptors are known to
recognize misfolded proteins and trigger stress responses
in various neurodegenerative diseases, TLR2 has not
been directly linked with the recognition of prion depos-
ition [40]. Interestingly, pharmacological inhibitors of
Toll-like-receptors, including TLR2, are being studied for
the treatment of various inflammatory diseases [41]).
The gene product of NCF1, or Neutrophil-cytosolic-
factor 1, is a component of the neutrophil NADPH, and
enzyme complex that produces a superoxide anion, a re-
active radical [42]. The gene product of PTPN6, also
called SHP-1 (Src homology region 2 domain-containing
phosphatase-1), codes for Tyrosine-protein-phosphatase
non-receptor type 6, a protein tyrosine phosphatase
involved in cell differentiation, in particular hematopoe-
tic cells [43]. B2M codes for β2 microglobulin, a compo-
nent of MHC class I molecules, and its expression in
neurons is regulated during injury [44]. These factors
point again to a major involvement of the innate immune
system in the pathogenesis of prion disease, and further-
more suggest the existence of new targets for possible
therapeutic intervention.
In another transcriptomics study by Sorensen et al.
[25], C57BL/6 or VMmice were inoculated intracerebrally
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those used in the study by Hwang et al. Seventeen
genes were found to be related to inflammation and
microglia activation. Ten of these genes were also
among the 333 DEG in the study by Hwang et al.: six
are located in our core network (ABCA1, CLU, TF and
SOX9) and two in our SCC (B2M and TGFB1). How-
ever, it should be noted that CLU was placed in the cell
death category and TF into the iron homeostasis cat-
egory by Hwang et al. All genes were similarly upregu-
lated in both studies. We decided to follow up with the
network analysis of data from the latter publication
since it was based on larger number of mice model
-prion strain combinations and therefore provided more
comprehensive list of DEGs. Although, both Hwang’s
and Sorensen’s studies included analysis aimed on iden-
tifying genes related to inflammatory processes, a stabil-
ity and dynamics analysis of the gene regulatory
network was performed for the first time in the present
study, allowing for the identification of brain inflamma-
tion as the main prion disease process among all the
possible others.
Inflammation response could be an overrepresented
functional category in a great number of diseases. In the
particular case of neurodegenerative diseases belonging
to the class of protein misfolding diseases, it is well
established that neuroinflammation plays a role. What
we consider remarkable and constitutes our main find-
ing is the key role that neuroinflammation plays in the
specific case of prion disease, connecting different func-
tional modules and constituting a switch that allows the
network to reach a self-maintained disease state, once
triggering factors (protein deposition and the formation
of amyloid plaques) initiate the process. According to
our simulations, the special topology that connects neu-
roinflammation elements (a cluster of positive feed-back
loops or SCC) makes the regulatory core sensitive under
perturbation to easily transit from inactive (healthy) to
active (diseased) states but become very stable once the
active state is reached.
To experimentally test the role of the genes of the
identified master regulatory core in prion disease, we en-
visage inoculating PrionSc into knockout mice that are
lacking one of the 16 SCC genes. Subsequently, the mice
would be analyzed pathologically with regard to neur-
onal function and death, as well as for DEGs for which
the network analysis would be repeated. This analysis
would be particularly interesting for the factors whose
explicit role has never been demonstrated in prion
pathogenesis (TLR2, NCF1, PTPN6).
Conclusions
In this study, we have carried out a network analysis
based on a recent study of prion disease in mouse inorder to gain insights into disease progression. We have
built a gene regulatory network consisting of genes dif-
ferentially expressed due to prion disease infection and
analyzed network topology and dynamics to identify key
network structures in disease progression. We have
identified an SCC that plays a crucial regulatory role in
the network and is capable of determining network
stability. This design resembles the “Medusa model”
described by Kauffman [45], in which a set of genes
represents a regulatory head and the remaining genes
represent arms controlled by the head.
The sixteen genes of SCC we have identified as master
regulatory core are capable of activating 58 further genes
which are differentially expressed in several mouse prion
models. These genes determine the stability of the net-
work and are also the critical connecting element be-
tween different pathological processes (disease-causing
prion replication and accumulation, immune response
and neuronal cell death).
Perturbation analysis of regulatory core genes demon-
strates that each gene is individually capable of trigger-
ing the transition between two stable states in the larger
network. A switch to the “on” state of any of the regula-
tory core locks the network the new stable, but diseased,
state. We hypothesize that this locking may be the cause
of the sustained immune response observed in prion dis-
ease, which could ultimately lead to prominent neuronal
cell death and the manifestation of clinical symptom
Methods
Generation of the global and core regulatory networks
The procedure for the network reconstruction consists
of the following steps: a) Obtaining a list of differentially
expressed genes. b) Connecting these genes using ex-
pression regulatory interactions from literature. c) Deter-
mining the core regulatory network.
a) Obtaining a list of differentially expressed genes.
A list of 333 DEGs was extracted from the results of
gene expression analysis experiments performed by
Hwang et al. [4]. These DEGs were found in all five
prion-wild type mouse combinations in the study.
b) Connecting differentially expressed genes using gene
regulatory interactions described in literature.
The ResNet mammalian database from Ariadne Gen-
omics http://www.ariadnegenomics.com/) was used to
construct a gene regulatory network. The ResNet data-
base includes biological relationships and associations,
which have been extracted from the biomedical litera-
ture using Ariadne's MedScan technology [46,47].
MedScan processes sentences from PubMed abstracts
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representing the meaning of each sentence. The ResNet
mammalian database stores information harvested from
the entire PubMed, including over 715,000 relations for
106,139 proteins, 1220 small molecules, 2175 cellular
processes and 3930 diseases. The focus of this database
is solely on human, mouse and rat.
We used the list of differentially expressed genes to
build a gene regulatory network without including any
additional genes not found in microarray experiments
resulting in a raw connected graph of 125 nodes and
255 interactions of known effect (positive or negative).
To build the network we included only literature evi-
dences of gene expresion regulation (directed and
signed interactions) and is therefore smaller and sparser
than it would have been if all possible known interac-
tions had been included (i.e. undirected protein-protein
interactions, indirect interactions). The expression pat-
terns of the DEGs were checked in the Prion Database
(http://prion.systemsbiology.net) to compare with top-
ology and associations’ logic leading to removal of
inconsistent 15 nodes and 81 edges. Additionally, dis-
covery of few errors in text mining process lead us to
further validation of the network. To avoid false associa-
tions we took all sentences used by Pathway Studio
(Ariadne Genomics) to determine gene associations and
searched for co-occurrence of specific words: modifiers
of sentence meaning, indicating increased risk of false
interpretation. In the next phase we checked manually
highly uncertain sentences and found two clearly wrong
associations: CD86 –+ > TGFB1 and CEBPA –+ >
CASP8. In summary, we obtained a final graph of 106
nodes and 169 edges we used for fragmentation analysis
in this paper. References for both raw and global net-
work interactions are included in the Additional file 1.
c) Determining the core regulatory network.
Given that only genes with incoming interactions are
relevant to the stability analysis, we had to identify genes
involved in regulatory feed-back loops, or circuits, and
genes regulated by them. For the first task we looked for
strongly connected components (SCCs) in the raw net-
work using Binom plugin [48] in Cytoscape [49].
An SCC is a network of nodes, where each node can
be accessed directly or indirectly from every other node
within the network or, in other words, if there exists a
path from each node in the network to every other node.
Due to the specific connectivity in a SCC, the informa-
tion can flow from one node to any other in the struc-
ture following at least one path. Such a path has to
respect the sense of the interactions (otherwise the com-
ponent is not strongly but weakly connected). Therefore,
the state of any node in the SCC can directly orindirectly affect the state of any other node. This mutual
influence between any pair of nodes within the SCC
indicates that the SCC may be a relevant stability-related
structure. We obtained a single SCC with 16 nodes.
After that, we expanded these cores iteratively by adding
first neighbors regulated by the SCC until no further
neighbors could be added. This yielded a network con-
sisting of the SCC and genes that are directly or indir-
ectly regulated by genes in the SCC (we call this the
“core network”). The core network including 74 nodes
and 125 interactions (all nodes with incoming interac-
tions) was used for stability and centrality analysis in this
paper. References for the interactions of the core net-
work are included in the Additional file 1.
Stability and perturbation analysis
For the stability analysis we used the SQUAD software
package [50], creating a discrete dynamical system that
allowed us to identify all the stable states of the system
with an asynchronous updating scheme [51] using a bin-
ary decision diagram based algorithm [52]. Subsequently,
a continuous dynamical system was created to identify
the stable states in this continuous model which are
located near to the stable states of the discrete system,
according to the method described by Mendoza et al.,
2006 [53], where the stable states of a Boolean model
are taken as initial conditions in the continuous model.
Gene perturbations were simulated in the continuous
model changing the expression values of specific genes.
We also calculated the stability of the SCC in isolation,
as well as the stability of the core network. More details
about stable states computation and perturbation simu-
lations are included in the Additional file 1.
Network properties
Fragmentation, betweenness centrality and inter-modular
participation measurements were employed to compare
the properties of SCC genes with other genes in the net-
work, and to determine key genes that might be potential
candidates for experimental validation.
In order to test the importance of the SCC in the net-
work’s connectivity, we examined the fragmentation ef-
fect of removing the 16 nodes belonging to the SCC in
comparison with the fragmentation effect of 1000 differ-
ent randomized removals of 16 nodes in the global net-
work of 106 nodes. The giant component is the biggest
connected subgraph found in the network for the given
fragmentation and thus a good measure for evaluating
such fragmentation [54,55].
Betweenness centrality was computed for all genes in
the network. The higher the value, the more central the
gene is in the network of reference, i.e. other genes are
more likely to be connected along the pathway involving
these genes [54] (see Additional file 1).
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tional and pathological process annotation of genes. The
participation coefficient P is a measure quantifying inter-
modular connections of genes. For any gene in question
P is greater than 0, if odds of inter-modular degree to
total degree of the gene is less than 1, which means it
has to have at least one connection within its own and
neighboring modules. Together with measure of within-
module connectivity, participation allows to define role a
node in the network ranging from most influential glo-
bal hub till peripheral node (global hub, connector hub,
provincial hub, kinless node, satellite connector, periph-
eral node and ultra-peripheral node). Such genes con-
nect various functional pathways and might therefore be
considered key regulators of cellular processes [56].
Functional analysis
Hwang et al. described four pathological features, which
were derived from GO attributes: (1) PrPSc replication
and accumulation, (2) microglia/astrocyte activation
(which we are calling immune response), (3) synaptic de-
generation and (4) neuronal cell death. We mapped
these pathological features on the nodes in our core net-
work and examined how the genes in our network may
relate to disease progression.
Additional file
Additional file 1: Supplementary material.
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